Jaktinib (<scp>JAK1</scp>/2 inhibitor): A momelotinib derivative with similar activity and optimized dosing schedule
Ayalew Tefferi, Naseema Gangat, Animesh Pardanani
Abstract
The authors declare no potential conflict of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Topics & Concepts
DosingScheduleDerivative (finance)PharmacologyChemistryComputer scienceMedicineBusinessFinanceOperating systemMyeloproliferative Neoplasms: Diagnosis and TreatmentChronic Myeloid Leukemia TreatmentsCytokine Signaling Pathways and Interactions